Genmab AS (GMAB)vsVertex Pharmaceuticals Inc (VRTX)
GMAB
Genmab AS
$26.11
+1.16%
HEALTHCARE · Cap: $15.94B
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 223% more annual revenue ($12.00B vs $3.72B). VRTX leads profitability with a 32.9% profit margin vs 25.9%. GMAB appears more attractively valued with a PEG of 1.62. VRTX earns a higher WallStSmart Score of 66/100 (B-).
GMAB
Buy54
out of 100
Grade: C-
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-187.1%
Fair Value
$10.47
Current Price
$26.11
$15.64 premium
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 26 of every $100 in revenue as profit
Attractively priced relative to earnings
Strong operational efficiency at 23.0%
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
3.0% revenue growth
Weak financial health signals
Earnings declined 94.4%
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : GMAB
The strongest argument for GMAB centers on Price/Book, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 25.9% and operating margin at 23.0%.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : GMAB
The primary concerns for GMAB are PEG Ratio, Revenue Growth, Piotroski F-Score.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
GMAB profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
GMAB carries more volatility with a beta of 0.75 — expect wider price swings.
VRTX is growing revenue faster at 9.5% — sustainability is the question.
GMAB generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 54/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Genmab AS
HEALTHCARE · BIOTECHNOLOGY · USA
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?